Drug intelligence / Profile preview

C-752

Development stage: Phase 1
Lead developer: Shanghai PerHum Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

C-752 is an autologous CAR-T cell therapy developed by Shanghai Perhum Therapeutics. It targets CD19 (B-lymphocyte antigen CD19) and acts as a CD19 inhibitor. The primary therapeutic areas are neoplasms, immune system diseases, and hemic and lymphatic diseases. Its main indication is for conditions involving CD19-positive B cells, such as certain types of lymphoma[8].

Other names: CPC752CPC-752CPC 752

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on C-752.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-752.

Explore the full profile